Insider tax-withholding share sale at Acrivon Therapeutics (NASDAQ: ACRV)

Rhea-AI Filing Summary

On 2026-07-21, Acrivon Therapeutics Chief Legal Officer Mary Miller had 573 shares of Common Stock sold at $1.76 per share. A note explains that the shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units. She continues to hold 82,194 shares directly after the transaction.

Insider Trade Summary

Net Seller: 573 shares

Net Sell 1 txn

Insider Miller Mary

Role Chief Legal Officer

Sold 573 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	573	$1.76	$1K

Holdings After Transaction: Common Stock — 82,194 shares (Direct)

Footnotes (1)

1. F1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Key Figures

Shares sold: 573 shares Sale price: $1.76 per share Shares held after: 82,194 shares

3 metrics

Shares sold 573 shares Common Stock sold on 2026-07-21

Sale price $1.76 per share Price for Common Stock sale on 2026-07-21

Shares held after 82,194 shares Direct Common Stock ownership following the transaction

Key Terms

restricted stock units, mandatory tax withholding requirement, open market or private transaction

3 terms

restricted stock units financial

"upon vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

mandatory tax withholding requirement financial

"Shares sold automatically to satisfy the mandatory tax withholding requirement"

open market or private transaction regulatory

"Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/23/2026 - 04:28 PM Accepted by SEC EDGAR 07/23/2026 - 04:28 PM Learn about SEC filing dates

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Mary Miller?

Acrivon Therapeutics reported that Chief Legal Officer Mary Miller had 573 shares of Common Stock sold. The sale occurred on 2026-07-21 and was tied to tax withholding obligations on vesting restricted stock units rather than a discretionary open-market trade.

How many ACRV shares did Mary Miller sell and at what price?

Mary Miller had 573 Acrivon Therapeutics shares sold at $1.76 per share. The transaction involved Common Stock and was recorded as a sale, while a related note clarifies it was executed to cover mandatory tax withholding on vested restricted stock units.

Why were Mary Miller’s Acrivon Therapeutics (ACRV) shares sold on 2026-07-21?

The shares were sold to satisfy mandatory tax withholding upon vesting of restricted stock units. This means the disposition was connected to an equity-compensation event rather than an elective portfolio change, according to the explanatory note attached to the transaction.

How many ACRV shares does Mary Miller hold after this transaction?

After the reported sale, Mary Miller directly holds 82,194 Acrivon Therapeutics shares. This post-transaction balance reflects her remaining Common Stock ownership following the 573-share sale executed for tax withholding associated with the vesting of restricted stock units.

Was Mary Miller’s ACRV share sale made under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox was not marked as applicable for this transaction. Instead, an explanatory note states the 573 shares were sold automatically to meet mandatory tax withholding on vested restricted stock units, not under a pre-arranged trading plan.

What type of security was involved in Mary Miller’s ACRV transaction?

The transaction involved Common Stock of Acrivon Therapeutics. The 573 shares sold at $1.76 per share were tied to the vesting of restricted stock units, with the sale executed to satisfy related mandatory tax withholding obligations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Mary

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/21/2026		S(1)		573	D	$1.76	82,194	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)